138 related articles for article (PubMed ID: 14690255)
1. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis.
Tanaka H; Suzuki K; Nakahata T; Tsugawa K; Ito E; Waga S
Clin Nephrol; 2003 Dec; 60(6):390-4. PubMed ID: 14690255
[TBL] [Abstract][Full Text] [Related]
2. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.
Tanaka H; Tsugawa K; Suzuki K; Nakahata T; Ito E
Pediatr Nephrol; 2006 Jul; 21(7):962-6. PubMed ID: 16773408
[TBL] [Abstract][Full Text] [Related]
3. Mizoribine for the treatment of lupus nephritis in children and adolescents.
Tanaka H; Tsugawa K; Tsuruga K; Suzuki K; Nakahata T; Ito E; Waga S
Clin Nephrol; 2004 Dec; 62(6):412-7. PubMed ID: 15630899
[TBL] [Abstract][Full Text] [Related]
4. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the tohoku pediatric study group.
Tanaka H; Oki E; Tsuruga K; Sato N; Matsukura H; Matsunaga A; Kondo Y; Suzuki J
Nephron Clin Pract; 2008; 110(2):c73-9. PubMed ID: 18758186
[TBL] [Abstract][Full Text] [Related]
5. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis.
Yumura W; Suganuma S; Uchida K; Moriyama T; Otsubo S; Takei T; Naito M; Koike M; Nitta K; Nihei H
Clin Nephrol; 2005 Jul; 64(1):28-34. PubMed ID: 16047642
[TBL] [Abstract][Full Text] [Related]
6. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis.
Tanaka H; Tsugawa K; Nakahata T; Kudo M; Suzuki K; Ito E
Clin Nephrol; 2005 Jun; 63(6):417-22. PubMed ID: 15960142
[TBL] [Abstract][Full Text] [Related]
7. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
8. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients.
Tanaka H; Tsugawa K; Oki E; Suzuki K; Ito E
Clin Rheumatol; 2008 Jan; 27(1):85-9. PubMed ID: 17483980
[TBL] [Abstract][Full Text] [Related]
9. Long-term intermittent pulse therapy with mizoribine attenuates histologic progression in young patients with severe lupus nephritis: report of two patients.
Tanaka H; Oki ES; Tsugawa K; Suzuki K; Tsuruga K; Ito E
Nephrology (Carlton); 2007 Aug; 12(4):376-9. PubMed ID: 17635753
[TBL] [Abstract][Full Text] [Related]
10. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy.
Kuroda T; Hirose S; Tanabe N; Sato H; Nakatsue T; Ajiro J; Wada Y; Murakami S; Hasegawa H; Ito S; Sakatsume M; Nakano M; Gejyo F
Mod Rheumatol; 2007; 17(3):206-12. PubMed ID: 17564775
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis.
Nishi E; Kameda H; Ogawa H; Nagasawa H; Takei H; Okuyama A; Kurasawa T; Kondo T; Nishimura K; Shirai Y; Sakai R; Ito T; Takeuchi T; Amano K
Mod Rheumatol; 2013 Jan; 23(1):97-103. PubMed ID: 22526831
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of mizoribine in the treatment of systemic lupus erythematosus in children.
Yoshidome K; Takei S; Imanaka H; Maeno N; Ohkawa T; Kawano Y
Pediatr Int; 2004 Aug; 46(4):444-9. PubMed ID: 15310311
[TBL] [Abstract][Full Text] [Related]
13. A case of lupus nephritis improved after appropriately adjusting the dosage of mizoribine.
Tsubouchi Y; Fukuda W; Kawahito Y; Kohno M; Wada M; Ishino H; Hamaguchi M; Yamamoto A; Kadoya M; Niimi M; Yoshikawa T
Mod Rheumatol; 2008; 18(1):91-5. PubMed ID: 18159569
[TBL] [Abstract][Full Text] [Related]
14. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose.
Tanaka H; Oki E; Tsuruga K; Yashiro T; Hanada I; Ito E
Clin Nephrol; 2009 Dec; 72(6):430-6. PubMed ID: 19954719
[TBL] [Abstract][Full Text] [Related]
15. Study of the efficacy of mizoribine in lupus nephritis in Chinese patients.
Zhang M; Xing CY; Liu J
Rheumatol Int; 2013 Nov; 33(11):2737-42. PubMed ID: 23797779
[TBL] [Abstract][Full Text] [Related]
16. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice.
Tanaka H; Watanabe S; Aizawa-Yashiro T; Oki E; Kumagai N; Tsuruga K; Ito E
Nephron Clin Pract; 2012; 121(3-4):c165-73. PubMed ID: 23327881
[TBL] [Abstract][Full Text] [Related]
17. Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis.
Tanaka H; Oki E; Tsuruga K; Aizawa-Yashiro T; Ito Y; Sato N; Kawasaki Y; Suzuki J
Clin Rheumatol; 2010 Sep; 29(9):1049-54. PubMed ID: 20490589
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis.
Tanaka H; Aizawa T; Watanabe S; Oki E; Tsuruga K; Imaizumi T
Lupus; 2014 Jul; 23(8):813-8. PubMed ID: 24651669
[TBL] [Abstract][Full Text] [Related]
19. Mizoribine pulse therapy for a pediatric patient with steroid-resistant nephrotic syndrome.
Tanaka H; Tsugawa K; Nakahata T; Kudo M; Onuma S; Kimura S; Ito E
Tohoku J Exp Med; 2005 Jan; 205(1):87-91. PubMed ID: 15635277
[TBL] [Abstract][Full Text] [Related]
20. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study.
Tanaka H; Oki E; Tsugawa K; Nonaka K; Suzuki K; Ito E
Lupus; 2007; 16(11):896-900. PubMed ID: 17971363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]